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http://www.biomedcentral.com/1471-2458/12/792RESEARCH ARTICLE Open AccessPre-pregnancy care for women with
pre-gestational diabetes mellitus: a systematic
review and meta-analysis
Hayfaa A Wahabi*, Rasmieh A Alzeidan and Samia A EsmaeilAbstract
Background: Pre-gestational diabetes mellitus is associated with increased risk for maternal and fetal adverse
outcomes. This systematic review was carried out to evaluate the effectiveness and safety of pre-pregnancy care in
improving the rate of congenital malformations and perinatal mortality for women with pre-gestational diabetes
mellitus.
Methods: We searched the following databases, MEDLINE, EMBASE, WEB OF SCIENCE, Cochrane Library, including
the CENTRAL register of controlled trials and CINHAL up to December 2011, without language restriction, for any
pre-pregnancy care aiming at health promotion, glycemic control and screening and treatment of diabetes
complications in women with type I or type II diabetes mellitus. Study design were trials (randomized and non-
randomized), cohort and case–control studies.
Results: Of the 2452 title scanned 54 full papers were retrieved of those 21 studies were included in this review.
Twelve cohort studies at low and medium risk of bias, with 3088 women, were included in the meta-analysis.
Meta-analysis suggested that pre-pregnancy care is effective in reducing congenital malformation, Risk Ratio (RR)
0.25 (95% CI 0.16-0.37), number needed to treat (NNT) 19 (95% CI 14–24), and perinatal mortality RR 0.34 (95% CI
0.15-0.75), NNT = 46 (95% CI 28–115).
Pre-pregnancy care lowers glycosylated hemoglobin A1c (HbA1c) in the first trimester of pregnancy by an average
of 1.92% (95% CI −2.05 to −1.79). However women who received pre-pregnancy care were at increased risk of
hypoglycemia during the first trimester of pregnancy RR 1.51 (95% CI 1.15-1.99).
Conclusion: Pre-pregnancy care for women with pre-gestational type 1 or type 2 diabetes mellitus is effective in
improving rates of congenital malformations, perinatal mortality and in reducing maternal HbA1C in the first
trimester of pregnancy. Pre-pregnancy care might cause maternal hypoglycemia in the first trimester of pregnancy.
Keywords: Pre-gestational diabetes, Pre-pregnancy care, Congenital malformations, Perinatal mortalityBackground
Pre-gestational diabetes mellitus (PGDM) and maternal
hyperglycemia during the time of organogenesis is a
known teratogen with detrimental effects on the fetal
heart, renal, musculoskeletal and central nervous systems
[1-3]. Population based studies showed that there is a five-
fold increase in the rate of cardiovascular malformations,
and more than twofold increase in the rate of neural tube* Correspondence: umlena@yahoo.com
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reproduction in any medium, provided the ordefects and urinary tract abnormalities in infants of dia-
betic mothers when compared to the background popula-
tion [1,2]. Moreover congenital malformations (GM) are
associated with increased risk of stillbirth and perinatal
mortality (PM) as they account for almost 50% of all
deaths of infants born to mothers with PGDM [4,5].
CM secondary to maternal diabetes can be prevented, in
great part, by optimizing maternal health in the pre-
pregnancy period. Glycemic control is one of the most im-
portant aspects of pre-pregnancy care (PPC) [6]; however
other aspects of care such as folic acid supplementation,
smoking cessation, screening and treatment of diabetesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are as important for improving maternal and fetal out-
comes and might be effective in reducing the rate of CM
to the background level [7-9].
The aim of this systematic review is to assess the effect-
iveness and safety of PPC in improving the CM and peri-
natal mortality for women with type 1 or type 2 PGDM.
Methods
Type of studies
We included in this review randomized trials (including
cluster and quasi randomized trials) and cohort and case
control studies, comparing the frequency of CM, PM, ma-
ternal hypoglycemia in the first trimester and the level of
glycosylated hemoglobin A (HbA1C) in diabetic women
who received PPC with those who did not receive PPC.
Type of participants
Women of reproductive age with type 1 or type 2 PGDM
who were not pregnant at the time of intervention.
Type of intervention
For the purpose of this review PPC is defined as the fol-
lowing either as sole intervention or in combination
1. Glycemic control by insulin and/or diet aiming at
fasting blood glucose ≤5.7 mmol/l or/and postprandial
blood glucose ≤7.8 mmol/l and/ or HbA1C ≤7.0%).
2. Women counseling and /or education about diabetes
complications during pregnancy, the importance of
glycemic control and self monitoring of blood
glucose level.
3. Pre-pregnancy screening and treatment of
complications of diabetes.
4. The use of contraception until optimization of
glycemic control is achieved.
5. Intake of multivitamin or folic acid in the
pre-pregnancy period.
Type of outcome
Maternal outcomes
1. HbA1C level in the first trimester.
2. Maternal hypoglycemia in the first trimester or any
other adverse effect reported by the authors.
Neonatal outcomes
1. CM related to maternal diabetes
2. Perinatal mortality.
Exclusion criteria
We excluded from this review reports which are not of
comparative design and reports of conference proceedingsor abstracts when there is no complete description of the
trial or study.
Search strategy
The search strategy was developed in consultation of an in-
formation retrieval specialist. We searched the following
databases, MEDLINE (1966-December 2011), EMBASE
(1980-December 2011), WEB OF SCIENCE (Science cit-
ation index-1970-December 2011), Cochrane Library up to
the latest issue 2011, including the CENTRAL register of
controlled trials CINHAL (Cumulative Index to Nursing &
Allied Health 1982 –December 2011) and Google Scholar.
(For full search strategy see Additional file 1: Appendix 1).
We reviewed the reference lists of all relevant studies
for any potential study not retrieved by the search strat-
egy. Unpublished reports were not actively sought and
there was no language limitation.
Identification of included studies
All titles and abstracts retrieved by the electronic search
were screened independently by the three reviewers, and
the studies which clearly did not meet the inclusion cri-
teria, were excluded. Copies of the full text of potentially
relevant studies and trials were obtained and their eligi-
bility was assessed independently by two reviews. Differ-
ences between reviewers were resolved by discussion or
by consulting the third reviewer.
Data extraction and studies assessment
Two reviews extracted data from the included studies
using a designed form. The accuracy of the extracted
data was checked by the third reviewer.
The Newcastle Ottawa Scale (NOS) was used for the as-
sessment of cohort, case control studies and non-
randomized trials [10]. Risk of bias in each study, was
assigned according to the number of items on the NOS
judged to be inadequate. We considered low risk of bias
when one item is inadequate, medium risk of bias when
up to three items are inadequate and high risk of bias
when more than three items are inadequate. Risk of bias
of the studies included in the review was assessed for each
study independently by two reviewers and any disagree-
ment was resolved by discussion with all the reviewers.
Data analysis was carried out with the use of Review
Manager Software 5.1.6 (Cochrane Collaboration, Oxford,
United Kingdom).
Meta-analysis was performed for studies with similar
design and type of intervention, which we assessed to be
at medium or low risk of bias using the fixed effect
model. Statistical heterogeneity was assessed by visual
inspection of forest plots, by performing x2 tests (asses-
sing the P value) and by calculating the statistic, which
describes the percentage of observed heterogeneity that
would not be expected by chance. If the P value was less
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geneity to be substantial. However subgroup analysis
was not possible in most of the cases due to the small
number of studies. Pooled data were presented as risk
ratio (RR) with 95% confidence intervals (95% CI) for di-
chotomous outcomes and as the means difference with
95% confidence intervals for continuous outcomes.Results
The search retrieved 2452 potentially relevant titles of
which the full text of 54 relevant reports were reviewed
(Figure 1). A total of 25 reports of 21 studies were
included in this review [7,8,11-33]. (Three articles
described the same cohort study with two interim [15,16]
and one final report [17], one study reported the out-
comes for the same cohort in two articles [7,27] and two
articles report the outcomes of one cohort with one in-
terim [29] and one final report [26]).
Twenty six studies were excluded because they did not
meet the inclusion criteria; two reports were of conference
proceedings and in one study data were not extractable
(Additional file 2: Appendix 2).26 studies did not meet 
the inclusion criteria
2 papers were conference
proceedings
1 Study data was not 
extractable
2398 papers were excluded by 
reviewing the title and/or the 
abstract
29 papers were excluded
2452 potentially relevant s
Figure 1 Process of selection of the studies for the systematic reviewOf the included studies, only one was a controlled
trial, 13 studies were prospective cohort studies, six
studies were retrospective cohort studies and one was a
case control study (Tables 1,2,3,4). The included studies
were conducted between 1983 and 2010 in Europe and
the United States of America, except for one study con-
ducted in Israel [19].
Assessment of the methodological quality of the included
studies
The cohort studies included in this review (Tables 1 & 2)
had adequate description of participants including de-
scription of some confounding factors such as the fre-
quency of renal and vascular complications of diabetes
between the PPC group and the control group. However
all studies did not address the effect of the presence of
confounding factors on the outcomes except for three
reports which used regression analysis to evaluate the ef-
fectiveness of the PPC [7,8,27].
In most of the cohort studies blinding of the control
group was adequate because they were recruited after
pregnancy when they attended for antenatal care, except
for two studies [22,26], in which inadequate blinding of 
25 papers were included 
in the review
tudies were retrieved
54 full text papers were retrieved
assessed for eligibility
.
Table 1 Characteristics of included prospective cohort studies
Study/ Year of
Publication
Reference (country)
Participants Intervention Outcome Risk of Bias (Notes)
Garcia-Patterson
1997 [18] (Spain)
66 participants with type I and type
II who attended the pre-pregnancy
clinic and 119 participants with type I
and type II diabetes who did not.
PPC included intensive insulin
therapy, self-monitoring of blood
glucose and dietary advice
The HbA1C was significantly better in the
PPC group than for the NPPC group
(p= 0.01).
There was no significant difference
between the two groups in
rate of congenital malformations.
Medium (The baseline characteristics in
relation to the vasculopathy are different.
No blinding for the outcome assessment).
Herman 1999 [20]
(USA)
24 women with type I diabetes
who attended the pre-pregnancy
clinic, and 74 women with type I
diabetes who did not attend the
pre-pregnancy clinic.
PPC included education,
counseling, glycemic control, and
assessment of complications of
diabetes such as nephropathy
and retinopathy
Women who had PPC had significantly
lower level of HbA1C at booking and
throughout pregnancy. There was no
significant difference between the two
groups in the frequency of infants with
congenital malformations.
High (The study was not designed to assess the
clinical outcomes of the pre-pregnancy care but
the differences in the socio-demographic
features between the groups who attend the
pr-pregnancy care and those who did not. The
target level for the glycemic control was not
clear and the absolute level of Hb A1C at
booking and all through pregnancy for the study
and the control groups was not mentioned)
Jaffiol 2000 [21]
(France)
21 IDDM attended the
pre-conception care and 40 did
not attend
PPC included education, glycemic
control, self monitoring of blood
glucose and contraception
There were significant reductions in the
PM and congenital malformations in the
PPC group as well as in the level of
maternal HbA1C in the 1st trimester
compared to the NPPC group.
Low (good report, clear intervention description,
the comparative groups received same antenatal
intervention. No blinding for outcome
assessment)
Jensen 1986 [22]
(Denmark)
9 women with insulin dependent
diabetes had pre-pregnancy care
and 11 women with insulin
dependent diabetic who did not
receive pre-pregnancy care.
PPC included continuous insulin
infusion initiated 2 months prior
to conception.
No significant difference in congenital
malformations and HAb1C level, between
the two groups
High (small number of study and control group,
many differences in the baseline characteristics
in the severity of diabetes, 5 of the 11 control
women were treated in the diabetic clinic in the
hospital before pregnancy so they knew about
the importance of glycemic control both groups
have the same HA1C levels in early pregnancy)
Kitzmiller 1991
[23] (USA)
84 women in pre-pregnancy care
and 110 women had no
pre-pregnancy care.
PPC included glycemic and dietary
control education, exercise and
contraception.
The frequency of congenital abnormalities
in the PPC group was significantly higher
than in the NPPC group (p <0.05).
Low (good report clear methodology)
Rosenn 1991
[24] (USA)
28 women in the pre-pregnancy
group and 71 in the control group
PPC included dietary advice and
glycemic control
HbA1C concentration in the PPC group
was lower than in the NPPC group
(p <0.0008). There were no congenital
malformations in either group.
Medium (52% of pre-pregnancy care patients
dropped out, no blinding in the assessment
of the outcome)
Temple 2006a [7]
2006b [27] (UK)
110 women with type I diabetes
attended the pre-pregnancy care
clinic and 180 women with type I
diabetes did not attend the
pre-pregnancy care clinic
PPC included: Glycemic control,
folic acid supplementation,
smoking cessation, education.
The rate of congenital malformations was
lower in PPC group compared to the NPPC
group (p< 0.065). PM was significantly
more in the latter group than the former
one (p< 0.026)
Low (Baseline characteristics in both groups were
similar; the prospective nature of the study
ascertained the completeness of the follow up,
the completeness of the baseline and the
outcome data. Use of appropriate statistical tests
such as logistic regression analysis confirmed the
association between the pre-pregnancy care
and outcomes).
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Table 1 Characteristics of included prospective cohort studies (Continued)
Willhoite 1993
[28] (USA)
62 women with either type I or
type II diabetes who received
pre-pregnancy counseling and 123
women witheither type I or type II
diabetes who did not receive
pre-pregnancy counseling
PPC included counseling by
health professional the control
group received no counseling.
PPC group had significantly less PM than
the NPPC group (OR3.9 CI 1.2-13.9) and
insignificantly less congenital
malformations (OR 4.2 CI 0.5-29.7)
High (Base line characteristics of the two groups
were significantly different in age, duration of
diabetes and smoking all are confounding factors
for the outcomes. The two groups did not
receive the same antenatal intra-partum and
postnatal care. The assessor of the congenital
malformation was not blinded)
Boulot 2003 [31]
(France)
172 women with either type I or
typeII diabetes who received PPC
and 260 women with either type I
or type II diabetes who did
not receive PPC
PPC included education,
assessment of diabetes
complications glycemic
control self monitoring of blood
glucose and contraception
PPC group had significantly less PM than
the NPPC group, (p <0.005) for type 1
diabetics and significantly less congenital
malformations, (p <0.005) for type 1
diabetics
Low (cases and control were well defined and
comparable, selection bias is unlikely as
consecutive cases were enrolled, the prospective
nature of the study ascertained the completeness
of the follow up, the completeness of the
baseline and the outcome data)
Galindo 2006 [30]
(Spain)
15 women with pre-gestational
diabetes received PPC and 112
women with pre-gestational
diabetes did not receive PPC.
PPC included education, glycemic
control self monitoring of
blood glucose
The frequency of congenital abnormalities
in the PPC group was 3/15 compared
to 14/112 in the NPPC group.
Low (cases and control were well defined and
comparable, selection bias is unlikely as
consecutive cases were enrolled, the prospective
nature of the study ascertained the completeness
of the follow up, the completeness of the
baseline and the outcome data)
Garcia Ingelmo
1998 [32] (Spain)
12 women with pre-gestational
diabetes received PPC and 12
women with pre-gestational
diabetes did not receive PPC.
PPC glycemic control. The frequency of congenital abnormalities
in the PPC group was 3/12 compared to
2/12 in the NPPC group. HbA1c was
significantly lower in the first trimester in
the PPC group compared to the NPPC
group, (p <0.01)
High (Both the study population and the control
were not representative of the general diabetic
population with frequency of diabetic vascular
complications approaching 50%. The PPC
components were not defined neither the
target blood glucose)
Murphy 2010
[8] (U.K)
181 participants with type I and
type II who received PPC and 499
participants with type I and type II
diabetes who did not receive PPC
PPC included: glycemic control,
folic acid supplementation,
smoking cessation, education.
The frequency of congenital abnormalities
in the PPC group was 0.7% compared to
5.6% in the NPPC group (p <0.02). The PM
in the PPC group was 0.7% which was
similar to 2.2% in NPPC (p <0.4).
Low (good report clear methodology)
Evers 2004 [33]
(Netherland)
271 women with type I diabetes
had planned pregnancy and 152
women did not plan their
pregnancy.
PPC had planned pregnancy
and folic acid supplementation
The frequency of congenital malformation
in PPC group was 11/271 (4.1%) compared
to 18/152 (12.2%) in the NPPC group. The
mean of HbA1C concentration of the PPC
group was significantly lower than the
NPPC group.
Medium (confounding factors such as smoking,
education level and social class were not
examined.The results of HbA1C during the first
trimester were not available for 29% of the whole
study group)
Key: HbA1c =Glycosylated Hemoglobin A, PPC = Pre-pregnancy Care, NPPC =No Pre-pregnancy Care, OR =Odd Ratio, IDDM= Insulin depended Diabetes Miletus, I = Confidence Intervals.
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Table 2 Characteristics of included retrospective cohort studies
Study/ Year of
Publication
Reference (country)
Participants Intervention Outcome Risk of Bias
Dunne 1999
[14] (UK)
47women with IDDM
12 of them attended
pre-pregnancy care clinic
and 35 women did not.
PPC included assessment
of diabetes complications
and glycemic control
The PPC group had significantly
lower level of HA1C level
compared to the NPPC group
(p< 0.008).
Medium (Due to the audit nature
of the report there is no clear
description of the intervention,
some important confounders
were not addressed such as
White’s classification and the
outcome assessment was
not blinded)
There were no congenital
malformations in both groups.
Damm 1989
[13] (Denmark)
197 attended PPC
and 61 didn’t attend
PPC included:
contraception and
glycemic control.
The rate of congenital
malformations was significantly
lower in the PPC group 1.0%
than the NPPC group 8.2%,
(p< 0.01).
No significant difference in the
level of HA1C during the first
trimester between the two group
High (unclear description of the
participants, the intervention and
the outcome, the data of the
pre-pregnancy care were a subset
of from different periods of the
study)
Goldman 1986
[19] (Israel)
44 women with type I
diabetes attended the
pre-pregnancy clinic
and 31women with
type I diabetes
did not attend
PPC included assessment
of diabetic complications,
Contraception advice,
Glycemic control and
dietary advice
The NPPC group had 3 infants
with congenital abnormalities
while the PPC did have any
infant with congenital
abnormalities
Low (Clear description of
participants and intervention,
noted confounding factors and
well presented results. There was
significant difference between
the two groups in the diabetes
complications before intervention)
Fuhrmann 1986
[17]& 1984 [16]&
1983 [15]
(Germany)
620 pregnant women
with insulin dependent
diabetes,183 received
pre-pregnancy care
437 women did not
PPC included: short
hospitalization every
3 month until conception,
education, self monitoring
of blood glucose, assessment
and treatment of diabetes
complications and
glycemic control
PPC group had significantly
lower rate of congenital
malformations 1.1%
compared to the NPPC group
7.0% (p< 0.01)
Medium (Well described
intervention, no blinding for the
outcome, no description of the
possible confounding factors)
Rowe 1987
[25] (UK)
21 IDDM 14 received
pre-pregnancy care
and 7 did not
PPC included The PPC group had
significantly better initial
HA1C level (p <0.0001).
High (Unclear description of
the participants, no description
of possible confounding factors,
no blinding in assessment of the
outcome, small group, high
target of HbA1C 5-9%)
glycemic control, counseling
and blood glucose
self monitoring
Steel 1990 [26]
& 1982 [29]
(UK- Scotland)
143 IDDM women
attended the
pre-pregnancy
care clinic and 96 IDDM
women did not attend
PPC included: education,
glycemic controlled
and contraception
PPC group had lower first
trimester HbA1C as compared
to NPPC group (p< 0.0001)
and lower rate of congenital
malformations (p< 0. 005),
maternal hypoglycemia was
significantly common in the
PPC group than the NPPC
(p< 0. 001)
Medium (Good description
of interventions, contamination
of the control who might know
about the usefulness of the and
the outcome assessment
was not blinded)
Key: HbA1C=Glycosylated Hemoglobin A, PPC = Pre-pregnancy Care, NPPC =No Pre-pregnancy Care, OR =Odd Ratio, IDDM= Insulin depended Diabetes Miletus.
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informed about the importance of the PPC and were
invited to attend. All participants received the same ante-
natal and post natal care except for one study [22] where
participants were followed up in different health settings.
All cohort studies had adequate follow up for partici-
pants except for two studies; in one study 52% of the
PPC group were lost to follow up and in the other study
29% of records of HbA1C in the first trimester for the
study cohort were missing [24,33]. The assessors of the
outcomes were not blinded to the participants’ allocation
except in one study [23].Some of the studies at high risk of bias were initially
designed to assess aspects of PPC other than its effect-
iveness in improving maternal and fetal outcomes, hence
the poor methodological design when assessed with the
NOS [14,20,28].
PPC in all the cohort studies included control and self
monitoring of blood glucose except for one which was
designed to examine the effectiveness of pre-pregnancy
counseling on fetal and neonatal outcomes [28]. In
addition to glycemic control, four studies included
screening and treatment of complications of diabetes in
the PPC program [14,17,19,20]. Three cohort studies
Table 3 Characteristics of included case–control studies
Study/ Year of Publication
Reference (country)
Participants Intervention Outcome Risk of Bias/Notes
Correa 2003 [12] USA Cases were 3278 Infants with
congenital malformations
related to diabetes. Controls
were 3029 infants without
congenital malformations.
Maternal diabetes and intake
of multivitamin were
evaluated as a risk factors
for congenital malformations
PPC included the use
of multivitamin for
3 month before
conception
The risk of congenital
malformations related to
diabetes was limited to
infants of f diabetic
mothers who had not
taken multivitamin
(OR 3.39 95% CI 1.79-8.63).
Mother who had taken
multivitamin had no increase
risk of congenital malformations
related to diabetes
(OR 0.15 95% CI 0.00-1.99)
Medium (clear definition
and selection of cases and
controls, and outcomes,
clearly defined outcome,
not clear if the
interviewers were blinded
to the outcome, recall
bias cannot be excluded
during the interviews)
Key: PPC = Pre-pregnancy Care, OR=Odd Ratio, CI = Confidence Interval.
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ing, control and self monitoring of blood glucose, folic
acid supplementation, smoking cessation advice and dis-
continuation of teratogenic drugs [7,8,27,33].
One case–control study was included in this review
[12] (Table 3). It examined the effectiveness of multivita-
min supplementation in the pre-pregnancy period in
preventing diabetes related CM. The study is at medium
risk of bias due to possibility of recall bias during the
interview of the mothers and the possibility that inter-
viewers were not blinded to the outcome.
One trial was included in this review [11] (Table 4).
The design of the trial was not clear as authors
reported it as a randomized trial but the method for
randomization was not described. There was no alloca-
tion concealment and lack of blinding introduced bias
because both groups were aware of the importance of
the glycemic control and the complications of diabetes
during pregnancy.
Only two studies in this review evaluated maternal
hypoglycemia, as an adverse effect of PPC [7,26].
Outcome of PPC
Similarity of participants, interventions and outcomes
in addition to the score of low or medium risk of bias,
made meta-analysis possible for 13 cohort studies
[7,8,14,17-19,21,23,24,26,30,31,33] with 3411 participantsTable 4 Characteristics of included controlled trials
Study/ Year of
PublicationReference
(country)
Participants Intervention Outcom
Pregnancy outcome
in Diabetes control
and complication
trial research group
1996 [11] (USA)
187 had pre-pregnancy
intensive insulin therapy
and 83 did not.
PPC included
glycemic control
and dietary
advice.
There w
PPC gro
Congen
5 in the
NPPC g
group w
to 8.8 ±
Key: HbA1C=Glycosylated Hemoglobin A, PPC = Pre-pregnancy Care, NPPC =No Pre(Tables 1, 2 & 5). Both dichotomous and continuous data
were pooled but only when standard deviation and similar
units were available for continuous data. Studies which
were at high risk of bias or of a design other than cohort
were excluded from the meta-analysis.
Meta-analysis suggested that pre-pregnancy care is ef-
fective in reducing CM, RR 0.25 (95% CI 0.16-0.37),
NNT19 (95% CI 14–24) (Figure 2), and PM RR 0.34 (95%
CI 0.15-0.75), NNT=46 (95% CI 28–115) (Figure 3).
There was no evidence of statistical heterogeneity.
Meta-analysis of pooled data showed that PPC lowers
HbA1C in the first trimester of pregnancy by an average
of 1.92% (95% CI 1.79-2.05) and while there is high het-
erogeneity (I2 = 98%) this variation is in the size of the
effect rather than the direction (Figure 4).
The use of multivitamins in the pre-pregnancy period as
a sole intervention, was evaluated by one case control
study [12] and was found not to be effective in reducing
the rate of CM, [Odd Ratio (OR) 0.15, 95% CI 0.00-1.99].
Similarly one study, at high risk of bias, evaluated
the effectiveness of pre-pregnancy counseling, as a sole
intervention, in improving fetal and neonatal out-
comes, showed improvement in PM, OR 3.9(95% CL
1.2-13.9) and no improvement in the rate of CM, OR
4.2(95% CL 0.5-29.7) [28].
Hypoglycemia as an adverse effect of PPC was evaluated
by two studies [7,26]. Meta-analysis of the pooled datae Risk of Bias/Note
as one still birth in the
up and 3 in the NPPC.
ital malformations were
PPC group and 4 in the
roup. Mean HbA1C in PPC
as7.4 ± 1.3 compared
1.7 in the NPPC group.
High (Unclear report of the outcome,
the control group was aware of the
importance of glycemic control and
was repeatedly advised to change into
intensive therapy when planning pregnancy.
So intervention was not restricted to the
pre-pregnancy group. No specific target
level of the blood sugar was stated for the
pre-pregnancy group)
-pregnancy Care.
Table 5 Pooled estimates effect of pre-pregnancy care
Dichotomous outcomes of pre-pregnancy care No of studies [reference] Risk Ratio [95% Confidence interval]
Congenital malformation 13 [7,8,14,17-19,21,23,24,26,30,31,33] 0.25 [0.16-0.37]
PM 6 [7,8,14,18,21,31] 0.34 [0.15-0.75]
Maternal hypoglycemia 2 [7,26] 1.51 [1.15,1.99]
Continuous outcomes Number of studies references Means difference (95% CI)
The difference in the level of glycosylated Hemoglobin A1c 5 [7,19,24,26,33] −2.43 [−2.27 to −2.58]
Wahabi et al. BMC Public Health 2012, 12:792 Page 8 of 12
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more frequent hypoglycemia than those who did not, RR
1.51 (95% CI 1.15-1.99) (Figure 5). However this outcome
is associated with marked heterogeneity (I2 = 85%).
Discussion
In this review PPC reduced the rate of CM from 7.4% to
1.9%; a rate similar to that reported for the background
population (Figure 2).
Reports from practically implemented PPC programs
support our findings of the effectiveness of PPC in im-
proving the rate of CM of infants of mothers with
PGDM [8,33]. However, many uncertainties remain
about the ability of these programs to reduce the malfor-
mation rate to that of the background population, par-
ticularly that a small but significant risk of CM
remained [33,34]. This observation might be due to
many factors, for instance the preferential effect of the
PPC on women with type 2 diabetes [8,35]; the influence
of other maternal risk factors for CM, such as maternal
obesity [36]; and the degree of comprehensiveness; and
coverage of services the program provides to preventStudy or Subgroup
Boulot 2003
Dunne 1999
Evers 2004
Fuhrmann 1986
Galindo 2006
Garcia-Patterson 1997
Glodman 1986
Jaffiol 2000
Kitsmiller 1991
Murphy 2010
Rosenn 1991
Steel 1990
Temple 2006a
Total (95% CI)
Total events
Heterogeneity: Chi² = 15.71, df = 11 (P = 0.15); I² = 30%
Test for overall effect: Z = 6.66 (P < 0.00001)
Events
2
0
11
2
3
2
0
0
1
1
0
2
2
26
Total
172
12
271
183
15
66
44
21
102
181
28
143
110
1348
Events
16
0
18
31
14
9
3
3
12
32
1
10
11
160
Total
260
35
152
437
112
119
31
40
131
495
71
96
180
2159
Weight
10.7%
19.4%
15.4%
2.8%
5.4%
3.4%
2.1%
8.8%
14.4%
0.7%
10.0%
7.0%
100.0%
Experimental Control
Figure 2 Risk Ratio for congenital malformation from 13 studies of w
receive pre-pregnancy care. PPC (experimental) = the group who receive
received pre-pregnancy care; CI = Confidence intervals.malformations beside glycemic control, such as folic
acid supplementation and discontinuing teratogenic
medication [8].
Population based studies showed a variable increase of
2.5 – 9 folds in the PM rate in diabetic mothers com-
pared to the background population [37]. For women
with PGDM 16-28% of PM is due to CM, and an add-
itional 21-41% is due to preterm delivery [38,39]. Since
the rates of both complications improve with PPC [9], it
is not surprising that the PM in women, who attended
PPC, in this review, is reduced by 66% compared to
those who did not (Figure 3).
During the period of organogenesis, maternal hyper-
glycemia is known to be associated with CM [34,40].
Population based studies showed a linear relationship
between maternal HbA1C level above 7%, in the first tri-
mester, and both CM and PM [41]. It is estimated that
an increase of 1% in the level of HbA1C in the first tri-
mester increases the odds of an adverse pregnancy out-
come by 5-6% [42].
The analysis of the pooled data in this review sug-
gested that PPC is effective in reducing the level ofM-H, Fixed, 95% CI
0.19 [0.04, 0.81]
Not estimable
0.34 [0.17, 0.71]
0.15 [0.04, 0.64]
1.60 [0.52, 4.93]
0.40 [0.09, 1.80]
0.10 [0.01, 1.90]
0.27 [0.01, 4.92]
0.11 [0.01, 0.81]
0.09 [0.01, 0.62]
0.83 [0.03, 19.73]
0.13 [0.03, 0.60]
0.30 [0.07, 1.32]
0.25 [0.16, 0.37]
Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
omen with pre-gestational diabetes mellitus who did or did not
d pre-pregnancy care; NPPC (control) = the group who did not
Study or Subgroup
Boulot 2003
Dunne 1999
Garcia-Patterson 1997
Jaffiol 2000
Murphy 2010
Temple 2006a
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.89, df = 5 (P = 0.97); I² = 0%
Test for overall effect: Z = 2.67 (P = 0.008)
Events
3
0
1
0
1
1
6
Total
172
12
66
21
181
110
562
Events
16
2
2
2
9
6
37
Total
260
35
119
40
495
180
1129
Weight
47.9%
5.0%
5.4%
6.6%
18.1%
17.1%
100.0%
M-H, Fixed, 95% CI
0.28 [0.08, 0.96]
0.55 [0.03, 10.79]
0.90 [0.08, 9.76]
0.37 [0.02, 7.43]
0.30 [0.04, 2.38]
0.27 [0.03, 2.24]
0.34 [0.15, 0.75]
Experimental Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 3 Risk ratio for (perinatal mortality) from six studies of women with pre-gestational diabetes mellitus who did or did not
receive pre-pregnancy care. PPC (experimental) = the group who received pre-pregnancy care; NPPC (control) = the group who did not
received pre-pregnancy care; CI = Confidence intervals.
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(Figure 4). However this result is associated with marked
statistical heterogeneity (I2 = 98%) (Figure 4). The reason
for this heterogeneity is the difference in ‘effect size’ pro-
duced by the PPC between the included studies. Evers
et al. reported a reduction of 8.5% in HbA1C between
the intervention and the control groups [33], while
Goldman et al. documented a reduction of 29% [19]. An-
other reason is the difference in the mean levels of
HbA1C of the intervention groups (target level), which
vary between 6.4% [33] and 8.5% [24,26]. Nevertheless
the overall estimate of the effect of PPC in reducing the
level of HbA1C is evident by the same direction of effect
in all included studies (Figure 4).
In the two studies that evaluated severe maternal
hypoglycemia as an adverse effect of PPC [7,26] the
pooled data showed an increased risk of hypoglycemia in
women who attended the PPC as compared to those who
did not (Figure 5). However, this result should be
approached with caution due to the marked statistical het-
erogeneity associated with the meta-analysis (I2 = 85%)
(Figure 5) and the small number of included studies. The
most likely explanation of the statistical heterogeneity is
the variable effect size of PPC on maternal hypoglycemiaFigure 4 First trimester mean value of glycosylated hemoglobin A1C
mellitus who did or did not receive pre-pregnancy care. PPC (experim
(control) = the group who did not received pre-pregnancy care; CI = Confidin the two studies. The study by Temple et al. [7] showed
no effect of PPC on maternal hypoglycemia, RR 1.18
(95% CI 0.88-1.58), while the study by Steel et al. showed
a significant increase in hypoglycemia among women
who attended PPC RR 3.19 (95% CI 1.56-6.53) (Figure 5).
We believe that the statistical heterogeneity is a reflection
of a true clinical heterogeneity. During the 16 year inter-
val between the two studies (Steel et al. 1990, Temple
et al. 2006) many innovations in the treatment of diabetes
in pregnancy have been developed. Such innovations
included patients’ education and counseling, intensive
self-monitoring of blood glucose and functional insulin
therapy [43]. Although meta-analysis suggested an
increased risk of severe hypoglycemia with PPC, we be-
lieve this is an unlikely adverse effect with modern treat-
ment and monitoring of diabetes during pregnancy.
In this review some isolated interventions in the pre-
pregnancy period were not as effective as a ‘program of
interventions’. One case control study addressed the ef-
fectiveness of multivitamin supplementation in the pre-
pregnancy period, as an isolated intervention, in reducing
the rate of CM and showed no effectiveness [12].
One study conducted an economic evaluation of PPC
and found that it is associated with considerable savings,from five studies of women with pre-gestational diabetes
ental) = the group who received pre-pregnancy care; NPPC
ence intervals.
Study or Subgroup
Steel 1990
Temple 2006a
Total (95% CI)
Total events
Heterogeneity: Chi² = 6.87, df = 1 (P = 0.009); I² = 85%
Test for overall effect: Z = 2.94 (P = 0.003)
Events
38
47
85
Total
143
110
253
Events
8
65
73
Total
96
180
276
Weight
16.3%
83.7%
100.0%
M-H, Fixed, 95% CI
3.19 [1.56, 6.53]
1.18 [0.88, 1.58]
1.51 [1.15, 1.99]
Experimental Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 5 Risk ratio of maternal hypoglycemia from two studies of women with pre-gestational diabetes mellitus who did or did not
receive pre-pregnancy care. PPC (experimental) = the group who received pre-pregnancy care; NPPC (control) = the group who did not
received pre-pregnancy care; CI = Confidence intervals.
Wahabi et al. BMC Public Health 2012, 12:792 Page 10 of 12
http://www.biomedcentral.com/1471-2458/12/792and reduced resource utilization [20]. However, popula-
tion based studies showed that only 34-38% of eligible
women receive PPC [3,28]. Hence further studies should
focus on how to increase utilization and uptake of PPC
and reduction of the rate of unplanned pregnancies
among diabetic women.
This systematic review provides a moderate to high
level of evidence for the effectiveness of PPC in the im-
provement of maternal and fetal outcomes [44]. It con-
firms previous findings by Ray et al. [6]; nevertheless,
the strength of our review is based on the comprehen-
sive evaluation of the available evidence on the effective-
ness and safety of PPC.
We are aware of the limitations of the observational
studies as the main source of evidence and the inherent
bias associated with the design; however, randomized
controlled trials to assess the effectiveness of PPC are
neither ethical nor feasible. Nevertheless the nature of
the intervention lent strength to the observational studies
by avoiding certain biases known to occur in such study
designs. Lack of allocation concealment and blinding of
participants were avoided by recruiting the intervention
and the control groups at different times during the
course of the study (pre-pregnancy period and antenatal
period). Additionally, and due to the relatively short dur-
ation of the pregnancy, attrition bias was noted in only
one study, [24] all other studies had complete follow-up of
both groups. The possible bias due to confounding factors
such as social class, level of education, subjects’ motiv-
ation, smoking, maternal age, obesity, parity and vascular
complications of diabetes, was noted by most of the stud-
ies but only two studies used the appropriate statistical
tests to quantify the effect of the PPC apart from the con-
founders [7,8]. It is worth noting that all but one of the
studies included in this review were conducted in Europe
and the United States of America [19], which limits the
generalizability of this review.
The review carries important implications for practice
and research as it highlights the importance of theintegration of PPC in the routine care of diabetic women
during their reproductive age. and have practical implica-
tion considering the recent report of the CEMCH [3]
which showed that CM rate in infants of diabetic mothers
in England, Wales and Northern Ireland is twofold, and
the PM was nearly fourfold, that of the background popu-
lation. These findings are also of a paramount importance
to many communities in the Middle East [45], North
Africa [46] and some communities in Asia [47] where the
rate of CM is very high due to many causes including ma-
ternal diabetes.
One of the main obstacles to the full implementation
of PPC programs is the failure of the target population
to utilize provided services [8]. We suggest that more re-
search is needed in methods of encouraging diabetic
women to utilize PPC.
Conclusion
PPC for women with type 1 or type 2 PGDM is effective
in improving rates of CM, PM and in reducing maternal
HbA1C in the first trimester of pregnancy. PPC might
cause maternal hypoglycemia in the first trimester of
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